The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice

BACKGROUND: Fingolimod (Gilenya®) is an oral medication for patients with highly active relapsing-remitting Multiple Sclerosis (RRMS). Clinical trials and post-marketing experience on more than 114,000 patients have established a detailed safety profile. Total patient exposure now exceeds 195,000 pa...

Full description

Saved in:
Bibliographic Details
Published in:BMC Neurol
Main Authors: Ziemssen, Tjalf, Kern, Raimar, Cornelissen, Christian
Format: Artigo
Language:Inglês
Published: BioMed Central 2015
Subjects:
Study Protocol
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4472406/
https://ncbi.nlm.nih.gov/pubmed/26084334
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-015-0342-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items